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Ubiquitin chains linked through lysine63 (K63) play a critical role in inﬂammatory signalling.
Following ligand engagement of immune receptors, the RING E3 ligase TRAF6 builds
K63-linked chains together with the heterodimeric E2 enzyme Ubc13-Uev1A. Dimerisation of
the TRAF6 RING domain is essential for the assembly of K63-linked ubiquitin chains. Here,
we show that TRAF6 RING dimers form a catalytic complex where one RING interacts with a
Ubc13~Ubiquitin conjugate, while the zinc ﬁnger 1 (ZF1) domain and linker-helix of the
opposing monomer contact ubiquitin. The RING dimer interface is conserved across TRAFs
and we also show that TRAF5–TRAF6 heterodimers form. Importantly, TRAF5 can provide
ZF1, enabling ubiquitin transfer from a TRAF6-bound Ubc13 conjugate. Our study explains the
dependence of activity on TRAF RING dimers, and suggests that both homo- and hetero-
dimers mediated by TRAF RING domains have the capacity to synthesise ubiquitin chains.
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Many immune signalling pathways rely on the synthesisof ubiquitin chains. Non-degradative ubiquitin chainshave important roles in determining the strength,
duration and type of inﬂammatory response by functioning as
molecular glue to stabilise signalling complexes. The extent of
ubiquitin chain synthesis following cytokine engagement deter-
mines whether downstream effector molecules are recruited and
activated. One E3 ligase with a critical role in many immune
signalling pathways is TNF receptor-associated factor 6 (TRAF6).
TRAF6 was initially identiﬁed because of its requirement for
interleukin1-receptor (IL1-R)-mediated activation of NF-κB1, but
is now known to play key roles in multiple signalling pathways
that control immunoregulatory functions2, 3. This is because
ubiquitin chains that are synthesised by TRAF6 serve as a plat-
form for the activation of downstream kinases such as TAK1 and
Akt4, 5.
Beﬁtting its central role in signalling, disruption of TRAF6
function has been linked to cancer and inﬂammatory disorders.
Ampliﬁcation of TRAF6 is associated with lung carcinoma6, and
poor prognosis for head and neck cancers7. Overexpression of
TRAF6 predicts a poor response to chemotherapy and radio-
therapy for colorectal cancer patients, with molecular studies
suggesting this is because TRAF6 regulates mitochondrial
translocation of p538. It has also been suggested that chronic
activation of TRAF6 is associated with aberrant splicing in hae-
mopoietic cells in myelodysplastic syndromes9.
TRAF6 belongs to the TRAF family of proteins (TRAF1–7),
which are deﬁned by the presence of a TRAF-C/MATH domain
and a TRAF-N or coiled coil (CC) domain10. These domains are
responsible for trimerisation and receptor binding10, 11. At their
N-termini TRAF2–7 have a RING domain, followed by a series of
zinc ﬁnger (ZF) domains10 (Fig. 1a). The RING domain is
common to many ubiquitin E3 ligases and, when dimeric, confers
on TRAF6 its ubiquitin chain-building activity12. In general,
RING E3 ligases bring together a substrate and a ubiquitin-
conjugated E2 enzyme resulting in transfer of ubiquitin to a
substrate lysine residue13, 14. There are ~30 E2s that assemble
ubiquitin chains of different types. TRAF6 preferentially builds
Lys63-linked ubiquitin chains by virtue of its interaction with the
Ubc13-Uev1A (also called Ube2N-Ube2V1) E2 complex follow-
ing engagement of receptors15. For other TRAFs, the E2 partners
are still to be deﬁned, and in fact TRAF2 contains an insertion in
its RING domain that appears to abrogate E2 binding16.
The RING domain not only recruits the E2~ubiquitin (E2~Ub)
conjugate, but also enhances the rate of ubiquitin transfer from
the E2 to the substrate17, 18. Recent studies have shown RING E3s
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Fig. 1 Structural characterisation of TRAF6 in complex with a Ubc13~Ub conjugate. a Schematic showing the domains of TRAF6, with the RZ3 and RZ1
constructs indicated below. ZF: zinc ﬁnger, CC: coiled-coil. b Multi-turnover activity assay comparing H. sapiens and D. rerio RZ3 TRAF6. Each form of
TRAF6 RZ3 was incubated with E1, Ubc13-Uev1A and ubiquitin at 37 oC for the indicated times. c Analytical size exclusion proﬁle of 250 µM DrRZ3 and the
isopeptide-linked Ubc13–ubiquitin conjugate (Ubc13~Ub) alone, or a mixture of the two were separated using a Superdex 200 10/300 column. Equivalent
fractions from each run were resolved by 16% SDS-PAGE. d Crystal structure of the complex of DrRZ3 and Ubc13~Ub showing the asymmetric unit. The
two TRAF6 monomers are in shades of green, ubiquitin is yellow and Ubc13 is blue. The disordered ZF2 and ZF3 are indicated in grey in the schematic
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achieve this by binding the E2 conjugated ubiquitin so that the
ﬂexible linker between ubiquitin and the E2 is bound to a groove
on the E219–24. While some RING-ubiquitin contacts are con-
served14, the additional interactions that prime the conjugate for
catalysis differ19, 20, 22–25. Like TRAF6, the activity of many RING
domains depends on their dimerisation because one RING
domain binds the E2, while residues from the C terminus of the
other RING protomer make essential contacts with
ubiquitin19, 2126. However, TRAF RING domains do not contain
a structural equivalent to the C-terminal tail that is essential for
many dimeric RING domains19, 21. Therefore, the mechanism by
which TRAFs stabilise the E2~Ub conjugate in the active (closed)
conformation remains uncertain. Furthermore, many receptor
complexes contain at least two different TRAF proteins. This
raises the possibility that TRAF heterodimers could be functional
—as observed for other RING E3 ligases such as MDM2/MDMX
and BRCA1/BARD127, 28.
In TRAF6, the RING together with ZF1 is required for E3
ligase activity12, 29. To identify the essential features that regulate
ubiquitin chain assembly by TRAF6 we have determined struc-
tures of the RING and ZF domains of TRAF6 bound to the
Ubc13~Ub conjugate in two crystal forms at 3.4 and 3.9 Å. Both
structures show that the Ubc13~Ub conjugate contacts both
protomers of the TRAF6 dimer. Importantly, ZF1 and the helix
that connects it to the RING domain contact ubiquitin and
enhance the rate of ubiquitin transfer. The structure and bio-
chemical assays explain why RING dimerisation is required for
assembly of ubiquitin chains by TRAF6, and account for the
importance of the ZF domains for activity. Furthermore, we also
show that the conserved RING dimer interface facilitates for-
mation of TRAF heterodimers that are functional E3 ubiquitin
ligases.
Results
Structure of the Ubc13~Ub conjugate bound to the TRAF6
dimer. To understand the molecular basis of Lys63 chain
synthesis by TRAF6 we sought to obtain the structure of TRAF6
bound to the Ubc13~Ub conjugate. The structure of the N-
terminal RING domain and the ﬁrst three ZFs of human TRAF6
(residues 50–211) has been reported previously12 and we initially
used a comparable human construct, referred to here as RZ3
(HsRZ3). Using GST-pulldown assays and analytical
size-exclusion chromatography, we established that HsRZ3 pre-
ferentially binds to the Ubc13~Ub conjugate (Supplementary
Fig. 1). Because TRAF6 HsRZ3 formed a stable complex with the
isopeptide-linked Ubc13~Ub conjugate, we puriﬁed the complex
and set up crystal trials. We obtained crystals of the
HsRZ3–Ubc13~Ub complex, but despite extensive optimisation
these diffracted to very low resolution. In an attempt to improve
crystal quality, we expressed and puriﬁed the equivalent RZ3
construct from Danio rerio TRAF6 (DrRZ3). The sequence of the
RING domain and ﬁrst ZF are highly conserved between DrRZ3
and HsRZ3 (Supplementary Fig. 2a), and together with Ubc13 and
Uev1A, DrRZ3 and HsRZ3 promoted the comparable synthesis of
ubiquitin chains (Fig. 1b). Additionally, DrRZ3 formed a stable
complex with the Ubc13~Ub conjugate (Fig. 1c) that could be
crystallised and diffracted to 3.9 Å (Table 1). The structure of the
complex was readily solved by molecular replacement (Supple-
mentary Fig. 2b).
In the structure, each asymmetric unit contains a single TRAF6
RZ3 dimer bound to two Ubc13~Ub conjugate molecules
(Fig. 1d). The central RING dimer is very similar to the
previously reported HsTRAF6 RZ3 dimer structure12, and an
overlay of the RING domains (residues 62–122) has a main-chain
RMSD of 1.0 Å. The contacts between the conjugate and TRAF6
are comparable on both sides of the dimer, but the structure is
asymmetric because there is no density for ZF2 and ZF3 in one
molecule of TRAF6. There was no evidence of any proteolysis,
and a large solvent channel occupies the space where ZF2 and
ZF3 are expected, suggesting that the two missing ZFs are highly
mobile in the absence of any crystal contacts. We therefore
expressed and puriﬁed a truncated construct that contained the
RING and just ZF1 of D. rerio TRAF6 (denoted DrRZ1). RZ1 and
RZ3 had a comparable level of activity (Supplementary Fig. 2c)
suggesting that the shorter construct contains the key determi-
nants of activity.
TRAF6 RZ1 formed a stable complex with Ubc13~Ub that
allowed puriﬁcation and crystallisation of the complex. The
structure was solved at 3.4 Å and contains two 1:1 DrRZ1-
Ubc13~Ub complexes in the asymmetric unit (Supplementary
Fig. 2d). Each DrRZ1-Ubc13~Ub conjugate complex sits on a
twofold axis and as a result the crystal contains two distinct
symmetrical complexes, which have a centrally positioned TRAF6
RING dimer associated with two Ubc13~Ub conjugates (Supple-
mentary Fig. 2e). The α-carbons of the two symmetrical RZ1
complexes overlay with an RMSD of 0.4 Å, and both are similar
to the RZ3 complex, with an RMSD of 0.9 and 1.5 Å. The contacts
between proteins are very similar in all TRAF6 complexes and
provide a molecular basis for understanding TRAF6 function.
Architecture of the TRAF6 catalytic complex. In the TRAF6-
Ubc13~Ub complex structure Ubc13 binds at the canonical sur-
face on the RING that includes loops 1 and 230, while the Ile36
patch of ubiquitin contacts Val108, Asp109 and Asn110 in the
RING26. As well as interacting with the RING domain, ubiquitin
contacts ZF1 and the connecting helix of the associated TRAF6
protomer (see below) (Fig. 1d, Supplementary Fig. 2e, f). In
addition, the Ile44-centred hydrophobic patch on ubiquitin
interacts with residues in α2 of Ubc13, and the conjugate adopts
Table 1 Data collection and reﬁnement statistics
DrRZ3 (5VO0) DrRZ1 (5VNZ)
Data collection
Space group P42212 C2221
Cell dimensions
a, b, c (Å) 181.11, 181.11, 97.41 138.36, 170.55, 97.31
α, β, γ (°) 90, 90, 90 90, 90, 90
Resolution (Å) 49.4–3.90 (4.36–3.90)a 42.3–3.40
(3.68–3.40)
Rmerge 0.167 (0.637) 0.119 (1.43)
I/σ(I) 7.9 (2.6) 9.7 (1.2)
CC1/2 0.993 (0.802) 0.997 (0.640)
Completeness (%) 97.9 (98.6) 99.6 (98.3)
Redundancy 4.9 (4.9) 7.1 (7.1)
Reﬁnement
Resolution (Å) 3.90 3.40
No. reﬂections 14,872 16,020
Rwork/Rfree 0.252 / 0.299 0.237 / 0.294
No. of atoms
Protein 5660 5321
Ion (Zn2+) 8 6
Water 0 0
B factors
Protein 113.0 159.5
Ligand/ion 94.21 131.6
R.m.s. deviations
Bond lengths (Å) 0.023 0.007
Bond angles (°) 1.54 1.06
Each structure was determined from a single crystal
aValues for the highest-resolution shell are shown in parentheses
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the ‘closed conformation’26. The same contacts are seen in all
complexes suggesting that the Ubc13~Ub conjugate preferentially
adopts the closed conformation when bound to TRAF6. Because
the conjugate contacts both RINGs in the dimer, this structure
accounts for the absolute dependence of ubiquitin chain assembly
on TRAF RING dimerisation12.
The C-terminal tail of ubiquitin has an extended conformation
stabilised by Asp89 and Asp119 of Ubc13, but does not appear to
be primed (Supplementary Fig. 2g). Two mutations (K92T and
K94Q) were introduced to prevent non-speciﬁc ubiquitylation of
Ubc13 and these probably account for the altered conformation
of the tail of ubiquitin. However, the overall architecture of the
TRAF6-Ubc13~Ub structure resembles the RNF4-Ubc13~Ub26
and TRIM25-Ubc13~Ub24 complexes and is compatible with the
Ubc13~Ub/Mms2 complex31 (Supplementary Fig. 3). This
structure therefore provides a framework for understanding the
transfer of ubiquitin onto Lys63 of another ubiquitin molecule,
allowing the synthesis of Lys63-linked chains by TRAF6.
Activation of the Ubc13~Ub thioester by ZF1 of TRAF6. In the
TRAF6-Ubc13~Ub complex, there are close contacts between
ubiquitin and two Arg residues in the linker-helix and ZF1 of the
interacting protomer. The sidechain of Arg126 from the linker-
helix sits at the RING dimer interface and contacts Gly87 of the
interacting RING domain, as well as the main chain of Lys33 at
the base of the α-helix in ubiquitin. Whereas, Arg147 from ZF1
packs against Asp32 of ubiquitin (Fig. 2a, b). The density for both
Arg residues was relatively well-deﬁned (Supplementary Fig. 2b,
f), and these residues are conserved in TRAF6 from a number of
vertebrate species (Supplementary Fig. 4a).
To determine the importance of contacts between ubiquitin
and the linker-helix and ZF1, we evaluated the activity of a series
of TRAF6 mutant proteins. All mutants were made in HsRZ3 and
as a result the numbering of the residues mutated differs from the
structure by one residue—we have attempted to make this clear
by naming residues that were shown to be important (e.g. Arglink
and ArgZF1). Single turnover assays where wild-type Ubc13 was
ﬁrst charged with Cy3-labelled ubiquitin containing a K63R
mutation (*UbK63R) were used to assess activity. The puriﬁed
conjugate was incubated with Uev1A and ubiquitin-D77 in the
presence or absence of TRAF6 variants. Fluorescence imaging
was used to monitor and quantify the appearance of diubiquitin
(*UbK63R-Ub) over time (Fig. 2c). In these assays, wild-type
HsRZ3 efﬁciently promoted discharge of Ubc13 and diubiquitin
formation, whereas the R125A (Arglink) mutant appeared
comparable to the no E3 control (Fig. 2c, d). Mutation of R146
(ArgZF1) also resulted in a substantial decrease in conjugate
discharge, while mutation of Ser129 on the next turn of the
linker-helix, and Glu144 did not impede activity. Similar results
were obtained with multi-turnover chain-building assays
(Fig. 2e).
While TRAF6 RZ3 does not form a highly stable dimer12
(Supplementary Fig. 4b), RING dimerisation is essential for
TRAF6 E3 ligase activity. To determine if the Arg mutants
inﬂuenced TRAF6 dimerisation, we analysed each variant by size
exclusion chromatography (Supplementary Fig. 4c). All mutants
were comparable to wild-type, except for the Arglink mutant
which eluted slightly later, suggesting that the RING dimer had
been destabilised. In the crystal structure Arglink contacts
ubiquitin (Supplementary Fig. 2b, f), but it seems that it is also
important for dimerisation. In this way Arglink resembles the
aromatic residue at the C terminus of the dimeric RINGs of RNF4
and ML-IAP, which play dual roles in stabilising the RING dimer
and the closed conformation of the conjugate21, 32. In contrast,
mutation of ArgZF1 does not destabilise the dimer, but abrogates
activity, suggesting that this residue contacts ubiquitin and
stabilises the closed conformation of the Ubc13~Ub conjugate.
Together these data suggest that ZF1 is critical for the assembly of
ubiquitin chains by TRAF6.
TRAF6 dimers with a single E2~Ub binding site are active. To
further investigate the importance of ZF1 and RING dimerisa-
tion, we assessed the ability of inactive TRAF6 mutants to recover
activity when mixed. In addition to the ArgZF1 mutant that
prevents ubiquitin binding, we used a I72D/L74R (IL/DR) mutant
of HsRZ3 that does not interact with Ubc13 because the E2
binding interface is disrupted12. We hypothesised that each
mutant would be inactive alone, but if the two TRAF6 RING
species associate, the Ubc13-binding and ubiquitin-binding sites
from different mutants could co-operate to form a complete
binding site for the E2~Ub conjugate.
As expected the activity of the isolated mutants was
signiﬁcantly impaired in both the chain building and single
turnover assays (Fig. 3). However, when the E2 interface mutant
was mixed with the ZF1 mutant (ArgZF1) activity was
considerably increased (Fig. 3). The increased activity must
originate from a population of mixed TRAF6 dimers that have a
single wild-type conjugate binding site comprising the E2 binding
site on one RING, and ZF1 of the interacting RZ3 molecule (as
indicated in schematic in Fig. 3a, c). Together, these data suggest
TRAF6 RING dimers that possess a single conjugate binding site
retain activity. As a result, activity can be used to assess
heterodimerisation of TRAF proteins.
TRAF RING heterodimerisation. Analysis of the sequences of
the RING and ZF domains from the four most similar TRAFs
(TRAF2, 3, 5 and 6) revealed an extended conserved region that
comprises the RING dimer interface and the ubiquitin binding
site on the linker-helix (Fig. 4a, b). The high level of similarity at
the dimer interface, but relative absence of sequence conservation
on the remainder of the surface, suggests that TRAF RING
domain heterodimers may form. In addition, the Arg in the
connecting helix is conserved in all four TRAFs, suggesting that
other TRAFs might have the capacity to interact with ubiquitin.
To investigate the formation of TRAF RING heterodimers, we
expressed RZ3 from TRAF5 and analysed its ability to interact
with TRAF6 using size-exclusion chromatography (Fig. 4c).
TRAF5 and TRAF6 eluted together and earlier than either protein
alone, suggesting that they preferentially form a stable dimer. In
support of the increased stability of the heterodimer the mixture
appeared to have greater activity than TRAF6 alone, even though
TRAF5 had diminished activity with Ubc13-Uev1A in both
single- and multi-turnover assays (Fig. 4d, left).
To conﬁrm that TRAF5-TRAF6 heterodimers were active, we
assessed the ability of TRAF5 to restore the activity of the Arglink
and ArgZF1 TRAF6 mutants. Substantial discharge of Ubc13~Ub
and recovery of chain-building activity was observed when
TRAF5 RZ3 was mixed with TRAF6 Arglink (Fig. 4d, middle),
showing that TRAF5 has an intact ubiquitin binding site. This
also shows that TRAF6 Arglink retains the ability to form dimers
with TRAF5 even though the mutation disrupts TRAF6
homodimers (Supplementary Fig. 4c), which is consistent with
the greater stability of the TRAF5-TRAF6 heterodimers. In
contrast, when the Arg in the linker-helix of TRAF5 (Arg101) was
mutated (R101A, referred to as RZ3-Arglink) activity was not
recovered in an equivalent mixing experiment. This is probably
because, like the equivalent TRAF6 mutant, the R101A mutation
destabilises dimer formation (Supplementary Fig. 4d). Together,
the data suggest that Arglink plays comparable roles in both
TRAF5 and TRAF6.
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TRAF5 RZ3 also recovered activity when mixed with the
TRAF6 ArgZF1 mutant in both single- and multi-turnover assays
(Fig. 4d, right). In TRAF5 ArgZF1 is replaced by a Gly, but the
adjacent residue is an Arg (Fig. 4b). We reasoned that small
adjustments in the structure of TRAF5 might allow this Arg
residue to fulﬁl the role of ArgZF1 in TRAF6. In support of this,
when TRAF5 in which Arg124 was mutated to Ala (R124A) was
mixed with the TRAF6 ArgZF1 activity was not recovered to the
same extent as observed when WT TRAF5 was included.
Together these data indicate that the linker-helix and ZF1 in
TRAF5 are important for activity. In addition, these results
provide evidence that TRAF RING heterodimers form and
promote ubiquitin transfer.
Discussion
TRAF proteins are adaptor molecules that have a trimeric ‘TRAF’
domain, which recognises the intracellular tails of membrane-
embedded cytokine receptors, and also a dimeric RING domain
that assembles ubiquitin chains in response to cytokine signalling.
Here we account for the importance of TRAF RING dimers and
show that the ZF1 domain of TRAF6 interacts with ubiquitin to
stabilise the closed conformation of the Ubc13~Ub conjugate.
Thus, ZF1 in TRAF6 plays a critical role in accelerating K63 chain
synthesis by Ubc13-Uev1A. We also demonstrate that the RING
domains of TRAF5 and TRAF6 form a stable heterodimer that is
an active E3 ligase, supporting the notion that TRAF hetero-
dimers can regulate ubiquitylation.
The conformation of the Ubc13~Ub conjugate bound to
TRAF6 resembles that reported for the RNF4 and TRIM25
complexes with Ubc13~Ub, and is compatible with the assembly
of K63-linked ubiquitin chains by TRAF624, 26. However, even
though the RING-E2~Ub interactions are conserved (Fig. 5a), the
RING-RING dimer interfaces vary, and accordingly, the ubiquitin
and E2 moieties bound to the distal RING are rotated relative to
the proximal molecules. As a result the critical cross-dimer ubi-
quitin-stabilising interactions are shifted (Fig. 5a, b) so that in
TRAF6 ubiquitin points towards the linker-helix and ZF1, where
it interacts with basic residues (Arglink and ArgZF1). In this way,
basic residues C-terminal to the TRAF6 RING domain appear to
b
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Fig. 2 The linker-helix and ZF1 of TRAF6 stabilise ubiquitin so that it is primed for attack. a Details of the molecular contacts between the RING dimer (two
shades of green) and ubiquitin from the RZ1 complex (chains A, B and C). Predicted polar contacts are indicated with dashed lines. Carbon atoms coloured
as in Fig. 1d, oxygen and nitrogen atoms coloured in red and blue, respectively. Numbering is as for D. rerio TRAF6. b Surface representation of the
TRAF6–ubiquitin interaction. Critical residues for stabilisation are in pink. Arg126 is labelled as Arglink; Arg147 as ArgZF1. c Ubc13 conjugated to
ﬂuorescently labelled ubiquitin was used in discharge assays in combination with no E3, wild-type HsRZ3, or mutant forms of TRAF6 as indicated. d
Quantiﬁcation of the formation of diubiquitin. Each experiment was performed in duplicate; error bars indicate range of measurement. e Chain-building
assay using the same mutants as in panel c. Reaction mixture was spiked with 10% ﬂuorescently labelled ubiquitin to allow visualisation of the chains
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fulﬁl the role of the well-established locking aromatic residue in
other dimeric RINGs, such as RNF4 and ML-IAP19, 21, 26.
A more general role for basic residues as the ‘locking pin’
seems likely because TRIM25 has similarly positioned residues,
Lys65 and Thr67, which make comparable contacts with ubi-
quitin (Fig. 5b)23, 24. In fact, the RING domains of TRIM25 and
TRAF6 overlay remarkably well, and this similarity extends
beyond the RING domain to include the TRAF6 linker-helix and
the α-helix that links the TRIM25 RING to its B-box domain. A
helix
C-terminal to the RING domain is also found in the structures of
other TRIMs, and in RNF125 and LNX2 (Fig. 5c)23, 33–35. Each of
these helices contains a basic residue in a position analogous to
Arglink and, if dimers form, these residues could contact ubiquitin
and stabilise the bound E2~Ub conjugate in the closed
conformation.
TRAF proteins function downstream of a variety of inﬂam-
matory sensors, including tumour necrosis factor (TNF), Toll-,
NOD- and RIG-I-like receptors10, 36. The speciﬁc signalling
outputs from these receptors are determined by the complement
of TRAF proteins recruited and the downstream effectors gen-
erated, in particular the ubiquitin chains which are built by TRAF
proteins2, 3, 10. Even though Lys63-linked chains synthesised by
TRAF6 have a critical role in signalling, the extent of ubiquitin
chain synthesis by other TRAFs is uncertain. The E2-interacting
surface of TRAFs is variable (Supplementary Fig. 5) and if E2s
bind16, it seems likely that each TRAF will bind to different E2s.
However, formation of TRAF RING heterodimers, as demon-
strated here, raises the possibility that even TRAFs that do not
bind E2s have the potential to regulate ubiquitin transfer by
providing a functional ZF1-linker-helix region to stabilise the
catalytically primed complex that is recruited by a partner TRAF.
TRAF RING heterodimers have not been reported before, but
multiple TRAFs are frequently found associated with signalling
complexes10, 36. Furthermore, the coiled coil/TRAF-C domains of
TRAF1 and TRAF2 are known to form a heterotrimer comprising
one copy of TRAF1 and two copies of TRAF237. TRAF1 does not
possess a RING domain and these 1:2 TRAF1/2 heterodimers
likely favour TRAF2 RING dimerisation. However, this raises the
potential that other TRAF heterotrimers might form. Irrespective
of whether heterotrimers form, there remains a crucial symmetry
mismatch in that trimeric TRAFs interact with trimeric receptors,
but RING domain dimers assemble ubiquitin chains. This sym-
metry mismatch is likely to be exacerbated in cells because many
cytokine receptors signal via receptor clustering38, where several
TRAF trimers would be expected to come into close proximity.
As a result, even if TRAF homotrimers form there is considerable
potential for TRAF RING heterodimers to bridge trimeric TRAF
complexes at the cell membrane. For example, in the simplest
case it would be anticipated that if TRAF homotrimers form and
a RING dimer is favoured, one RING domain would be free to
interact with the RING of a neighbouring trimer as in Fig. 6.
Alternatively, if RING heterodimers are favoured it is possible
that two trimers might associate to form three RING hetero-
dimers. Other combinations are also possible and may be
favoured by membrane clustering as suggested previously12, 39.
Regulation of TRAF proteins is complex, and much work
remains to establish how trimeric TRAFs couple with dimeric
RING domains to transduce signals. However, our data not only
account for the importance of TRAF RING dimers, but also
provide a mechanism by which clustering of cytokine receptors
could elicit differential ubiquitin ligase activity—and the assembly
of distinct ubiquitin chains from homo- and heterodimeric TRAF
complexes. The nature and extent to which such signalling occurs
in a cellular setting will depend on identiﬁcation of the E2s bound
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by other TRAFs, and thus the ubiquitin chains assembled, as well
as systematic analysis of TRAF RING heterodimer formation.
Despite these uncertainties, heterodimeric TRAF RING domains
bridging a network of trimeric TRAF proteins is an attractive
mechanism to account for the complexity of signals elicited
downstream of many cytokine receptors.
Methods
Protein production and puriﬁcation. All proteins were expressed in Escherichia
coli BL21 (DE3) (Novagen). Ubiquitin and ubiquitin variants were expressed as
untagged proteins40. After overnight expression at 18 °C, the E. coli cells were
harvested and re-suspended in 50 mM ammonium acetate pH 4.5 containing 1 mM
EDTA. After sonication and clariﬁcation, the supernatant was injected on a 5 mL
HiTrap SP column (GE) and eluted with a 50 mL linear gradient from 0 to 1M
NaCl, in 50 mM ammonium acetate pH 4.5, 1 mM EDTA. The peak fractions were
pooled and injected on a HiLoad Superdex 75 16/600 column (GE) equilibrated in
20 mM Tris-HCl pH 7.5, 150 mM NaCl.
The human E1 protein was expressed with an N-terminal His6 tag41. After lysis
in 20 mM Tris-HCl pH 8.5, 100 mM NaCl, 5 mM imidazole, the supernatant was
loaded on a 5 mL HisTrap column. A linear 50 mL gradient from 5 to 250 mM
imidazole was applied. The fractions containing E1 were injected on a HiLoad
Superdex 200 16/600 column (GE) equilibrated with 20 mM Tris-HCl pH 7.5, 150
mM NaCl.
Homo sapiens TRAF6 constructs (HsRZ3: residues 50–211, 20.0 kDa; HsRZ1:
50–159, 13.8 kDa) were cloned into pET21d encoding a C-terminal His tag, while
Danio rerio TRAF6 constructs (DrRZ3: residues 50–213, 19.7 kDa; DrRZ1: residues
50–159, 13.7 kDa) were in pET24b. All TRAF6 constructs were induced at an O.
D.600nm of 0.6 with 0.2 mM IPTG and 0.1 mM ZnCl2 and incubated at 28 °C for 4
h. Cells were sonicated in 50 mM Tris-HCl pH 7.5 and 350 mM NaCl, before being
clariﬁed and loaded into a 5 mL HisTrap FF column (GE). After elution, the peak
fractions were loaded into a 10/300 Superdex 200 column (GE). TRAF5 was cloned
into the pGEX6P3 vector containing an N-terminal GST tag. Protein expression
was induced as for TRAF6, but was incubated at 18 °C overnight. Cells were
sonicated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, and the lysate was clariﬁed
and bound to glutathione sepharose resin for 1 h. The GST tag was cleaved by
overnight incubation with 3C protease. The soluble fraction was loaded on a 5 mL
HiTrap Q column, eluted with a linear 1M NaCl gradient, and cleaned up by size-
exclusion chromatography as for TRAF6. Ubc13 and Uev1A were expressed as N-
terminal GST-fusion proteins and puriﬁed using glutathione afﬁnity, proteolysis of
the GST tag, and size-exclusion chromatography.
For stable Ubc13~Ub conjugate formation, a mutated form of Ubc13 was used.
This variant included C87K, K92T and K94Q mutations to allow formation of a
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stable isopeptide-linked conjugate (Ubc13~Ub) while disrupting formation of other
species as a result of non-speciﬁc transfer from the E1. For production of
isopeptide-linked conjugates, 40 µM of pure Ubc13 (C87K, K92T, K94Q) was
mixed with 80 µM wild-type ubiquitin, 1 μM E1, 1 mM ATP, and ATP cycling
buffer containing 25 mM Tris-HCl pH 9.0, 5 mM MgCl2, 10 mM phosphocreatine
(Sigma) and 0.5 UmL−1 creatine phosphokinase (Sigma)42. The reaction was
incubated at 37 °C for 16 h. The resulting Ubc13~Ub conjugate was puriﬁed using a
26/600 Superdex 75 column (GE) equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM
NaCl.
Pull-downs and analytical size-exclusion chromatography. To assess binding of
TRAF6 RZ3 to Ubc13 and Ubc13~Ub conjugates, GST-fused Uev1A was mixed
with TRAF6, Ubc13 and Ubc13~Ub conjugates. The incubations were performed
in PBS containing 0.2% TWEEN 20 and 1mM DTT, at 4 °C for 1 h. Subsequently,
the resin was washed three times with PBS with 0.2% TWEEN 20 before being
mixed with SDS loading dye and separated by SDS PAGE. The gels were stained
with Coomassie Blue.
Analytical size-exclusion chromatography (SEC) was performed by injecting
200 µL of puriﬁed protein, or mixtures of proteins (DrRZ3 and Ubc13~Ub at 250
µM; HsRZ3 and Ubc13/Ubc13~Ub at 50 µM), over a 10/300 Superdex 200 (GE)
equilibrated with 20 mM Tris-HCl pH 7.5, 150 mM NaCl at 0.5 mLmin−1. The
recovered fractions were analysed by SDS PAGE. For the analysis of TRAF6
proteins, each protein was injected over a 10/300 Superdex 200 Increase at 40 µM.
For determination of the oligomeric status of TRAF6, multiangle light scattering
(MALS; Dawn 8+, Wyatt) coupled to a Superdex 200 10/300 GL (GE) was used.
Each TRAF5 protein was analysed at 40 µM using a 10/300 Superdex 75 Increase
column.
Crystallisation and structure solution. Puriﬁed D. rerio TRAF6 (RZ1 and RZ3)
were mixed with isopeptide-linked Ubc13~Ub conjugate for 30 min on ice before
being separated using size-exclusion chromatography over a 10/300 Superdex 200
column (GE). The fractions corresponding to the TRAF6-Ubc13~Ub complex were
pooled, concentrated to ~2 mgmL−1, and the PACT and JCSG+ crystal screens
(Molecular Dimensions) were set up with a 1:1 ratio of protein to precipitant in
sitting well plates (Swissci). Trays containing DrRZ3 and DrRZ1 resulted in crystals
within 12 h in many conditions, which diffracted to ~8 Å. Crystals of DrRZ3 were
grown in 100–200 mM Na/K tartrate, 11–15% PEG 3350 and 100 mM Bis-Tris
propane pH 7.5; DrRZ1 crystals were produced in 0.05–0.3 mM sodium citrate, 100
mM Bis-Tris propane, and 17–23% PEG 3350. Fine tuning of the crystal condi-
tions, changing drop ratios to 2:1 (protein: well solution), and slowing down the
growth of crystals using microbatch resulted in DrRZ1 and DrRZ3 crystals that
diffracted to 3.4 and 3.9 Å, respectively, on MX2 at the Australian Synchrotron43.
Data sets were collected for each crystal form, and processed and scaled using
XDS44. Data were merged with Aimless45, and the structures were solved with
Phaser-MR46 using the complex of Ubc13-TRAF6 RING domain (PDB: 3HCT12)
followed by ubiquitin (PDB: 1UBQ47). For one of the DrRZ3 molecules, two of the
three ZF could be automatically placed, while the third ZF had to be manually built
using Coot48. Structures were reﬁned using Refmac49, while Coot was used to
iteratively build missing residues, including the C-terminal tail of ubiquitin. For
DrRZ3, 92.1% of residues are in favoured regions, 6.6% in allowed regions and 1.3%
are outliers. For DrRZ1, 96.3% of residues are in favoured regions, 3.5% in allowed
regions and 0.2% are outliers.
Puriﬁcation of ﬂuorescently labelled conjugate. Fluorescently tagged ubiquitin
was produced by introducing a Cys residue before the beginning of the ubiquitin
sequence, resulting in Met-Cys-ubiquitin. To label the free Cys puriﬁed ubiquitin
was reduced with 1 mM TCEP and mixed with 5 µL of Cy3 for 1 h. The sample was
desalted (5 mL HiTrap desalting, GE) to remove excess dye and incubated in the
dark at room temperature for ~16 h to allow unconjugated ubiquitin to form
disulphide-linked dimers. Subsequently, the mixture was separated on a 16/600
HiLoad Superdex 75 column (GE) and the second peak corresponding to mono-
meric ubiquitin was pooled and concentrated to ~2 mgmL−1. Thioester-linked
conjugate containing ﬂuorescent ubiquitin was produced and puriﬁed using similar
conditions as before,50 except Ubc13 with a K97R mutation was mixed with ubi-
quitin, E1 and ATP cycling buffer at pH 7.5. The thioester charging reaction was
incubated at 37 °C for 20 min before the conjugate was puriﬁed using a 10/300
Superdex 75 column (GE) equilibrated with 20 mM MES pH 6.5, 150 mM NaCl.
The fractions containing conjugate were immediately ﬂash frozen in liquid
nitrogen.
Ubiquitylation assays. For multi-turnover ubiquitylation assays, 0.1 µM E1, 6 µM
Ubc13 and Uev1A, 50 µM ubiquitin, and 4 µM TRAF proteins (wild-type or
mutants) were mixed together in a buffer containing 20 mM Tris-HCl pH 7.5, 2
mM DTT, 2 mM ATP, 5 mM MgCl2 and 0.1 M NaCl, and incubated at 37 ºC. For
ﬂuorescently labelled multi-turnover assays, the reaction mixture was spiked with
10% ﬂuorescent ubiquitin. At the indicated times, the reactions were quenched by
adding SDS-PAGE loading buffer containing β-mercaptoethanol. Proteins were
separated using 16% SDS-PAGE, 10–18% gradient SDS-PAGE (homemade) or
commercial (4–12% bis-Tris SDS PAGE, Invitrogen) gels. Fluorescence was imaged
using an Odyssey FC imaging system (LI-COR) at 600 nm with a 2 min exposure.
Gels were stained with Coomassie blue.
For single-turnover discharge assays, 10 µM puriﬁed thioester linked
Ubc13~UbK63R conjugate was mixed with 15 µM Uev1A, 50 µM D77 ubiquitin (a
ubiquitin variant where the C-terminal Gly is mutated to Asp to prevent charging
by E1), and 4 µM TRAF proteins and incubated at 20 or 37 °C for the indicated
time. The ﬁnal pH of the discharge reactions was 7.0. Reactions were quenched
with non-reducing SDS-PAGE loading dye containing 10 mM N-ethylmaleimide.
For quantiﬁcation of ﬂuorescently labelled conjugate, gels were scanned as for the
multi-turnover assays and the intensity of ﬂuorescent bands was quantiﬁed using
Image Studio Lite (LI-COR).
Data availability. The coordinates and structure factors for TRAF6 RZ3 and RZ1
complexes with Ubc13~Ub have been deposited to the Protein Data Bank under
the accession codes 5VO0 and 5VNZ, respectively. All other data are available from
the corresponding authors upon reasonable request.
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